Hackbarth Corinne J, Chen Dawn Z, Lewis Jason G, Clark Kirk, Mangold James B, Cramer Jeffrey A, Margolis Peter S, Wang Wen, Koehn Jim, Wu Charlotte, Lopez S, Withers George, Gu Helen, Dunn Elina, Kulathila R, Pan Shi-Hao, Porter Wilma L, Jacobs Jeff, Trias Joaquim, Patel Dinesh V, Weidmann Beat, White Richard J, Yuan Zhengyu
Versicor, Inc., Fremont, California 94555, USA.
Antimicrob Agents Chemother. 2002 Sep;46(9):2752-64. doi: 10.1128/AAC.46.9.2752-2764.2002.
Peptide deformylase (PDF) is a prokaryotic metalloenzyme that is essential for bacterial growth and is a new target for the development of antibacterial agents. All previously reported PDF inhibitors with sufficient antibacterial activity share the structural feature of a 2-substituted alkanoyl at the P(1)' site. Using a combination of iterative parallel synthesis and traditional medicinal chemistry, we have identified a new class of PDF inhibitors with N-alkyl urea at the P(1)' site. Compounds with MICs of <or=4 micro g/ml against gram-positive and gram-negative pathogens, including Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae, have been identified. The concentrations needed to inhibit 50% of enzyme activity (IC(50)s) for Escherichia coli Ni-PDF were <or=0.1 micro M, demonstrating the specificity of the inhibitors. In addition, these compounds were very selective for PDF, with IC(50)s of consistently >200 micro M for matrilysin and other mammalian metalloproteases. Structure-activity relationship analysis identified preferred substitutions resulting in improved potency and decreased cytotoxity. One of the compounds (VRC4307) was cocrystallized with PDF, and the enzyme-inhibitor structure was determined at a resolution of 1.7 A. This structural information indicated that the urea compounds adopt a binding position similar to that previously determined for succinate hydroxamates. Two compounds, VRC4232 and VRC4307, displayed in vivo efficacy in a mouse protection assay, with 50% protective doses of 30.8 and 17.9 mg/kg of body weight, respectively. These N-alkyl urea hydroxamic acids provide a starting point for identifying new PDF inhibitors that can serve as antimicrobial agents.
肽脱甲酰基酶(PDF)是一种原核金属酶,对细菌生长至关重要,是抗菌药物开发的新靶点。所有先前报道的具有足够抗菌活性的PDF抑制剂在P(1)'位点都具有2-取代烷酰基的结构特征。通过迭代平行合成与传统药物化学相结合的方法,我们确定了一类在P(1)'位点具有N-烷基脲的新型PDF抑制剂。已鉴定出对革兰氏阳性和革兰氏阴性病原体(包括金黄色葡萄球菌、肺炎链球菌和流感嗜血杆菌)的最低抑菌浓度(MIC)≤4μg/ml的化合物。抑制大肠杆菌镍-PDF 50%酶活性所需的浓度(IC50)≤0.1μM,证明了这些抑制剂的特异性。此外,这些化合物对PDF具有高度选择性,对基质溶素和其他哺乳动物金属蛋白酶的IC50始终>200μM。构效关系分析确定了能提高效力并降低细胞毒性的优选取代基。其中一种化合物(VRC4307)与PDF共结晶,并以1.7Å的分辨率确定了酶-抑制剂结构。该结构信息表明,脲化合物的结合位置与先前确定的琥珀酸异羟肟酸酯相似。两种化合物VRC4232和VRC4307在小鼠保护试验中显示出体内疗效,50%保护剂量分别为30.8和17.9mg/kg体重。这些N-烷基脲异羟肟酸为鉴定可作为抗菌剂的新型PDF抑制剂提供了一个起点。